CNBC – Pfizer and BioNTech’s three-dose Covid vaccine for children 6 months to 5 years old was 80% effective at preventing illness during the omicron wave, according to preliminary clinical trial results released Monday.
A third dose of the vaccine elicited a strong immune response and was well tolerated by the kids with a majority of the side effects mild to moderate, according to the companies.
BioNTech CEO Ugur Sahin said the companies plan this week to complete their application asking the Food and Drug Administration to authorize the vaccine for emergency use. Pfizer CEO Albert Bourla said he hopes the vaccine will be available to younger kids as soon as possible… read more